Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody
US9676867B2 · kind B2 · utility
10Cited by
21References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 8, 2013 |
| Grant date | Jun 13, 2017 |
| Priority date | — |
| Expiry date | Oct 9, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.